SOURCE: Geneart AG

January 16, 2007 05:03 ET

GENEART awarded contract by SAIC-Frederick, Inc. for the US National Cancer Institute part of the National Institutes of Health

REGENSBURG, GERMANY -- (MARKET WIRE) -- January 16, 2007 --


- SAIC-Frederick, Inc. awards contract for the production of 2,000 to 3,000 genes with a stop codon and the same genes without the stop codon

- The expected order volume amounts up to USD 6.5 million

- GENEART will perform the synthesis within the scope of the NIH's "Mammalian Gene Collection Program"

Regensburg, 16. January, 2007 - GENEART today announced that the company is a recipient of a contract for the synthesis of 2,000 to 3,000 genes and 2,000 to 3,000 gene variants thereof. The expected order volume amounts up to USD 6.5 million. The genes to be synthesized by GENEART will be added by the National Cancer Institute to the NIH'S comprehensive collection of genes of humans and mice to provide an important resource for basic and biomedical research.

Within the scope of the "Mammalian Gene Collection (MGC) Program", the National Institutes of Health (NIH) has been working on creating a comprehensive, publicly accessible cloned gene library of humans and mice since 1999. The goal of Mammalian Gene Collection is to include at least one defined full-length clone of each known gene sequence of these two species. The Mammalian Gene Collection is the largest publicly available cDNA library, and of crucial importance for molecular research in mammals. All genetic sequences are freely accessible via a database; the associated genes can be ordered by any researcher.

The GENEART is to synthesize up to 3,000 genes and 3,000 gene variants for the Mammalian Gene Collection over the next eight to ten months. The subset to be synthesized mainly comprises genes which could not be obtained at all or only at significant higher cost by using conventional methods (from cDNA libraries or RT-PCR).

"We are very happy that we were chosen for this project. The record size and the scientific importance of this order confirm that our company is the worldwide leader in the field of gene synthesis", stated Mr. Christian Ehl, CEO / CFO of GENEART AG.

"By consistently increasing capacities while simultaneously miniaturizing and automating the production process, we are now able to manufacture genes in an industrial process, "just like on an assembly line". Gene synthesis is therefore becoming a standard tool worldwide in the field of modern biotechnological and pharmaceutical research. The de novo synthesis of genes, however, not only provides cost advantages for our clients, but also offers researchers completely new possibilities in terms of designing new medications, vaccines, and industrial enzymes. We are therefore certain that this is just the beginning of a revolutionary development in the field of DNA engineering and synthetic biology", Prof. Dr. Wagner, CEO / CSO of GENEART AG points out.

For further inquiries, please contact:

Bernd Merkl                     Frank Ostermair
Josef-Engert-Str. 11            Haubrok Investor Relations GmbH
D-93053 Regensburg, Germany     Maximilianstraße 45
Tel.: +49-(0)941-942 76 - 38    80538 München
Fax: +49-(0)941-942 76 - 11     Tel: 089-21027-204
ir@geneart.com                  Fax: 089-21027-298
www.geneart.com                 f.ostermair@haubrok.de
Background information:

About GENEART AG

GENEART was founded in 1999. Today, the company ranks as the leading global specialist in gene synthesis for research institutions, the pharmaceutical industry and for enterprises in biotechnology and chemistry. GENEART offers integrated product systems based on gene synthesis for the development of innovative drugs, in particular for DNA- and protein-based therapeutics and vaccines, and for the identification of improved industrial enzymes. Service offerings range from synthesizing artificial genes according to DIN EN ISO 9001:2000, via constructing gene libraries in the field of combinatorial biology, to the production and development of DNA- based active components. The team of more than 80 employees in Regensburg and with the subsidiary GENEART Inc. in Toronto/Canada reached break even in 2005. Since May 2006 GENEART AG is listed at the German Stock Exchange.

About the NIH:

The National Institutes of Health (NIH) - The Nation's Medical Research Agency - is comprised of 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical, and translational medical research, and investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

The project has been funded in whole with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. N01-CO-12400. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Service, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information